Japanese
Title分化型甲状腺癌転移巣に対する131I治療 - SPECTによる吸収線量評価と治療成績 -
Subtitle原著
Authors有竹澄江*, 日下部きよ子**, 金谷信一**, 金谷和子**, 中野敬子**, 太田淑子**, 牧正子**, 重田帝子**
Authors(kana)
Organization*横浜労災病院放射線科, **東京女子医科大学放射線科
Journal核医学
Volume30
Number1
Page51-60
Year/Month1993/1
Article原著
Publisher日本核医学会
Abstract「要旨」131I治療開始後5年以上経過観察を行った分化型甲状腺癌患者18例において, 腫瘍吸収線量と治療効果, 予後との関連, および吸収線量評価の臨床的意義について検討した. 腫瘍吸収線量は131I治療施行時に腫瘍の累積放射能と重量をSPECTより求めMIRD法にて計算した. 治療後軽快中の患者は8例で腫瘍吸収線量は10-630Gy(重量2-22g, 有効半減期1.2-3.5日)で経過観察期間は8. 6±0.9年であった. 10例は131I治療が無効で腫瘍吸収線量は5-81Gy(重量7-215g, 有効半減期1.3-5.3日)で経過観察期間は5.6±2.5年であった. 治療有効例では初回131I治療時に全例94Gy以上の高い吸収線量が測定された. また131I治療有効, 無効例ともに131I治療を重ねるごとに腫瘍吸収線量の低下が認められ, 治療効果を得るには初回治療が重要と考えられた. SPECTより求められた腫瘍吸収線量は治療効果をよく反映し, 患者の予後を推定する上で臨床上有用と考えられた.
Practice臨床医学：一般
Keywords131I-therapy, Thyroid carcinoma, Quantitatives SPECT, Absorbed dose.
English
Title131I-Therapy of Differentiated Thyroid Carcinoma with Distant Metastases - Relation between Absorbed Dose by Quantitative SPECT and Outcome of the Patients in Thyroid Carcinoma -
SubtitleOriginal Articles
AuthorsSumie ARITAKE*, Kiyoko KUSAKABE**, Shinichi KANAYA**, Kazuko KANAYA**, Keiko NAKANO**, Toshiko OTA**, Masako MAKI**, Akiko SHIGETA**
Authors(kana)
Organization*Department of Radiology, Yokohama Rousai Hospital, **Department of Radiology, Tokyo Women's Medical College
JournalThe Japanese Journal of nuclear medicine
Volume30
Number1
Page51-60
Year/Month1993/1
ArticleOriginal article
PublisherTHE JAPANESE SOCIETY OF NUCLEAR MEDICINE
Abstract[Summary]The correlation of absorbed doses of tumors in 18 patients of differentiated thyroid carcinoma with distant metastases, who were treated by 131I and followed over 5 years, with their outcome were analyzed and the clinical significance of determination of absorbed dose was discussed. Radioactivities of 131I in the tumors were measured by using SPECT at the time of therapy. Absorbed dose was calculated based on the MIRD equation. Outcome of 8 patients were evaluated as good and their absorbed dose was 10-630 Gy with 2-22 g of tumor volume, 1.2-3.5 days of effective half life (EHL) and follow-up term was 8.6 +- 0.9 years. The absorbed dose of 10 patients whose outcome were evaluated as poor, was 5-81 Gy with 7-215 g of tumor volume, 1.3-5.3 days of EHL and follow-up term was 5.6 +- 2.5 years. The initial treatment seemed to be important for 131I therapy, since the absorbed doses in the following therapy became reduced. When the absorbed dose of the tumor exceeded over 94 Gy at initial treatment, good clinical courses were obtained. These results indicate that the quantitative SPECT for 131I therapy is clinically valid and that the calculated absorbed doses correlate well with outcome of the patients.
PracticeClinical medicine
Keywords131I-therapy, Thyroid carcinoma, Quantitatives SPECT, Absorbed dose.

【全文PDF】